细辛脑联合多索茶碱治疗慢性阻塞性肺病疗效观察

目的：观察细辛脑联合多索茶碱治疗慢性阻塞性肺疾病急性加重期（AECOPD）的临床疗效。方法：将164例AECOPD患者随机分为观察组（82例）和对照组（82例），对照组予低流量吸氧、抗炎、抗感染、纠正水电解质紊乱等综合治疗，观察组在此基础上加用注射用细辛脑、多索茶碱静脉治疗。观察两组治疗前后症状、体征改善情况及血气分析变化。结果：观察组与对照组临床总有效率分别为93．9％、81．7％（P〈0．05），观察组在发热、咳嗽咳痰、喘息症状消失时间，以及肺部罗音减少50％以上时间均显著短于对照组（P〈0．01），在FEV1、FEV1／FVC、PEF、PaO2、PaCO2等指标也显著优于对照组（P〈0．01）。结论：在常规治疗基础上加用细辛脑、多索茶碱可以有效提高AECOPD患者的临床疗效。

Doxofylline plus Asaroneon for Chronic Obstructive Pulmonary Disease

Objective： To observe the efficacy of doxofylline and asarone on treatment of acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. Methods： A total of 164 patients with AECOPD were randomly divided into two groups （82 cases） and control group （82 cases）. The control group were treated with the low-flow oxygen, anti-inflammatory, anti-infective, correct water and electrolyte disturbance such as combined therapy. On the basis of the control group, the observation group were added with injection asarone and doxofylline in vein. Symptoms, signs and blood gas analysis were observed before and after the treatment. Results： The total effective rate of the observation group and control group were 93.9% and 81.7%, respectively （P〈0.05）. the duration of fever, cough, expectoration, wheezing and 50% reduction in pulmonary rales in the observation group were significantly shorter than that in the control group （P〈0.01）. FEV1, FEV1/FVC, PEF, PaO2, PaCO2 and other indicators in the observation group were also significantly better than that in the control group （P〈0.01）. Conclusion： On the basis of conventional therapy, asarone combined doxofylline can improve the clinical efficacy in patients with AECOPD.